Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010

Vaccine

Volumn 30, Issue SUPPL. 2, 2012, Pages

  Ouandaogo, Claude Roger ^a   Yaméogo, Téné M ^d   Diomandé, Fabien V K ^c   Sawadogo, Charles ^a   Ouédraogo, Bassirou ^a   Ouédraogo Traoré, Rasmata ^b   Pezzoli, Lorenzo ^e   Djingarey, Mamoudou H ^c   Mbakuliyemo, Nehémie ^c   Zuber, Patrick L F ^c  

^a MINISTÈRE DE LA SANTÉ   (Burkina Faso)

^b Centre Hospitalier Universitaire (CHU)   (Burkina Faso)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d Meningitis Vaccine Project (MVP)   (Burkina Faso)

^e Consultant for the Meningitis Vaccine Project ^*  (United Kingdom)

Author keywords

AEFI; Africa; MenAfriVac; Monitoring; Pharmacovigilance; Safety; Vaccine

Indexed keywords

MENINGOCOCCUS VACCINE;

ABSCESS; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADOLESCENT; ADULT; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; ASTHENIA; BRONCHOSPASM; CHILD; CONVULSION; CRYING; DIZZINESS; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; ECZEMA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; INFANT; LETHARGY; LOCAL SKIN REACTION; LYMPHADENOPATHY; MALE; MASS IMMUNIZATION; MYALGIA; NEISSERIA MENINGITIDIS; NODULE; PASSIVE IMMUNIZATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RASH; SCALP PRURITUS; SCHOOL CHILD; SIDE EFFECT; SLEEPING DISORDER; SYNCOPE; URTICARIA; VOMITING;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; BURKINA FASO; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; MASS VACCINATION; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; YOUNG ADULT;

EID: 84861170825     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.112     Document Type: Article

References (19)

1. LaForce F.M., Konde K., Viviani S., Préziosi M.P. The Meningitis Vaccine Project. Vaccine 2007, 25(September (Suppl. 1)):A97-A100. Epub 2007 May 7.
2. Bishai D.M., Champion C., Steele M.E., Thompson L. Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa. Health Aff (Millwood) 2011, 30(June (6)):1058-1064.
3. Sow S.O., Okoko B.J., Diallo A., Viviani S., Borrow R., Carlone G., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. New Engl J Med 2011, 364(June (24)):2293-2304.
4. Global Advisory Committee on Vaccine Safety, 3-4 December 2009. WER 2010, 85(5):31-32.
5. Global Advisory Committee on Vaccine Safety, 16-17 June 2010. WER 2010, 85(30):285-292.
6. Vogt R.L., LaRue D., Klaucke D.N., Jillson D.A. Comparison of an active and passive surveillance system of primary care providers for hepatitis, measles, rubella, and salmonellosis in Vermont. Am J Public Health 1983, 73(July (7)):795-797.
7. Ciofi Degli Atti M.L., Salmaso S., Bella A., Arigliani R., Gangemi M., Chiamenti G., et al. Pediatric sentinel surveillance of vaccine-preventable diseases in Italy. Pediatr Infect Dis J 2002, 21(August (8)):763-768.
8. Bentsi-Enchill A.D., Zongo I., Khamassi S., Pless R., Thombiano R., Tiéndrebéogo S., et al. Monitoring of adverse events during the 2003 mass vaccination campaign with a trivalent meningococcal A/C/W135 polysaccharide vaccine in Burkina Faso. Vaccine 2007, 25(September (Suppl. 1)):A72-A78. Epub 2007 May 7.
9. Pöllabauer E.M., Petermann R., Ehrlich H.J. Group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine: a meta-analysis of immunogenicity, safety and posology. Hum Vaccin 2005, 1(July-August (4)):131-139. Epub 2005 July 13.
10. Destefano F., Pfeifer D., Nohynek H. Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data. Bull World Health Organ 2008, 86(May (5)):373-380.
11. Mark A., Carlsson R.M., Granstrom M. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine 1999, 17(April (15-16)):2067-2072.
12. WHO Supplementary information on vaccine safety. Part 2: background rates of adverse events following immunization 2000, WHO/V&B/00.36, Available on: http://www.who.int/immunization_safety/publications/aefi/en/.
13. Kane M. Unsafe injections. Bull World Health Organ 1998, 76(1):99-100.
14. Cutts F.T. Advances and challenges for the expanded programme on immunization. Br Med Bull 1998, 54(2):445-461.
15. Kohl K.S., Marcy S.M., Blum M., Connell J.M., Dagan R., Hansen J., et al. Fever after immunization: current concepts and improved future scientific understanding. Clin Infect Dis 2004, 39(3):389-394.
16. Michael M.S., Kohl K.S., Dagan R., Nalin D., Blum M., Jones M.C., et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004, 22(5-6):551-556.
17. Müller O., Traoré C., Becher H., Kouyaté B. Malaria morbidity, treatment-seeking behaviour, and mortality in a cohort of young children in rural Burkina Faso. Trop Med Int Health 2003, 8(April (4)):290-296.
18. Laribière A., Miremont-Salamé G., Reyre H., Abouelfath A., Liège L., Moore N., et al. Surveillance of adverse effects during a vaccination campaign against meningitis C. Eur J Clin Pharmacol 2005, 61(December (12)):907-911. Epub 2005 November 18.
19. Vellozzi C., Broder K.R., Haber P., Guh A., Nguyen M., Cano M., et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010, 28(October 45):7248-7255. Epub 2010 September 16.